From a commenter on Derek Lowe’s blog a few days back.
(Lowe is a PhD experimental anti-cancer biochemist. Careful with data and conclusions.)
I haven’t checked these out, but they seem interesting.
Regarding hydroxychloroquine:
https://justthenews.com/politics-policy/coronavirus/bahrain-hydroxychloroquine-success-response-covid-19
Other sidechain hydroxylated 4-aminoquinolines, ie. amodiaquine https://en.wikipedia.org/wiki/Amodiaquine , and its analog FGI-104 https://en.wikipedia.org/wiki/FGI-104 , share antiviral properties that have been characterized as being broad spectrum, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776286/ .
It is suggested that these compounds somehow interfere with the virus particles’ ability to hijack host cell’s membrane remodeling machinery ESCRTs https://en.wikipedia.org/wiki/ESCRT , needed to endocytize (internalize) the membrane attached virons into the cytoplasm , and then exocytosis or budding of newly formed virus particles from the host cell following replication.
Doesn’t acknowledge the time of Wuhan/Hubei introduction of the virus.
More important than any other metric IMO.
Just seems silly to me to ignore that. We know where the virus came from. The question of “when” it did matters.